Cargando…
Evaluating the administration costs of biologic drugs: development of a cost algorithm
Biologic drugs, as with all other medical technologies, are subject to a number of regulatory, marketing, reimbursement (financing) and other demand-restricting hurdles applied by healthcare payers. One example is the routine use of cost-effectiveness analyses or health technology assessments to det...
Autores principales: | Tetteh, Ebenezer K, Morris, Stephen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883988/ https://www.ncbi.nlm.nih.gov/pubmed/26208926 http://dx.doi.org/10.1186/s13561-014-0026-2 |
Ejemplares similares
-
Administration costs of intravenous biologic drugs for rheumatoid arthritis
por: Soini, Erkki J, et al.
Publicado: (2013) -
Discrete-choice modelling of patient preferences for modes of drug administration
por: Tetteh, Ebenezer Kwabena, et al.
Publicado: (2017) -
Costs of mass drug administration for scabies in Fiji
por: Mow, Maria, et al.
Publicado: (2022) -
Cost-effectiveness and Pricing of Antibacterial Drugs
por: Verhoef, Talitha I, et al.
Publicado: (2015) -
National Mass Drug Administration Costs for Lymphatic Filariasis Elimination
por: Goldman, Ann S., et al.
Publicado: (2007)